Workflow
三友医疗涨2.15%,成交额3698.24万元,主力资金净流入995.62万元

Core Viewpoint - Sanyou Medical has shown a mixed performance in stock price and financial metrics, with a notable increase in revenue and net profit year-on-year, indicating potential growth in the medical device sector [1][2]. Financial Performance - As of June 30, 2025, Sanyou Medical achieved a revenue of 250 million yuan, representing a year-on-year growth of 17.77% [2]. - The net profit attributable to shareholders reached 36.60 million yuan, marking a significant year-on-year increase of 2083.64% [2]. - The company has distributed a total of 113 million yuan in dividends since its A-share listing, with 39.75 million yuan distributed over the past three years [3]. Stock Performance - On September 22, 2023, Sanyou Medical's stock price increased by 2.15%, reaching 19.99 yuan per share, with a total market capitalization of 6.666 billion yuan [1]. - Year-to-date, the stock price has risen by 13.23%, while it has seen a slight decline of 0.05% over the last five trading days and a drop of 11.00% over the last 20 days [1]. - The stock has appreciated by 24.77% over the past 60 days [1]. Shareholder Information - As of June 30, 2025, the number of shareholders increased by 12.61% to 7,108, while the average number of circulating shares per person decreased by 11.20% to 34,954 shares [2]. - Among the top ten circulating shareholders, notable changes include a decrease of 1.5154 million shares held by Rongtong Health Industry Flexible Allocation Mixed A/B and an increase of 0.1646 million shares held by Southern Medicine Health Flexible Allocation Mixed A [3]. Business Overview - Sanyou Medical, established on April 19, 2005, and listed on April 9, 2020, specializes in the research, production, and sales of medical orthopedic implants and ultrasonic power devices and consumables [1]. - The company's main revenue sources include spinal implant consumables (63.80%), active devices and supporting accessories (31.51%), trauma implant consumables (3.53%), and others (1.16%) [1]. - The company operates within the pharmaceutical and biological industry, specifically in the medical device and consumables sector [1].